Skip to main content

Table 1 CHEK2*1100delC in breast cancer cases and healthy controls

From: Frequency of CHEK2*1100delC in New York breast cancer cases and controls

  Positive for CHEK2*1100delC (%)
Controls  
Jewish (New York) 3/1096 (0.3%)
Non-Jewish (New York) 2/569 (0.4%)
Total 5/1665 (0.3%)
BRCA1/2-negative individuals of mixed ethnicity with breast cancer from families with 3 or more cases of breast cancer 0/67 (0.0%)
BRCA1/2 Ashkenazi founder mutation-negative individuals with breast cancer from families with 3 or more cases of breast cancer 1/33# (3.0%)
BRCA2-negativei individuals of mixed ethnicity with male breast cancer 0/16 (0.0%)
Individuals with bilateral breast cancer of mixed ethnicity unselected for family history 0/46 (0.0%)
Individuals with unilateral breast cancer unselected for family history matched for age, ethnicity 1/46 (2.2%)
Clinic-ascertained individuals of Ashkenazi Jewish descent with bilateral breast cancer 1/46 (2.2%)
Clinic-ascertained individuals of Ashkenazi Jewish descent with unilateral breast cancer matched for age, family history 0/46 (0.0%)
  1. #This case previously reported in CHEK2 Breast Cancer Consortium [5].